Cara Therapeutics reported $226.57M in Assets for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Assets Change
Acadia Pharmaceuticals ACAD:US $ 612.77M 11.48M
Acelrx Pharmaceuticals ACRX:US $ 56.13M 15.84M
Aerie Pharmaceuticals AERI:US $ 385.34M 10.21M
Cara Therapeutics CARA:US $ 226.57M 2.71M
Chugai Pharma 4519:JP Y 1625604M 40656M
Depomed DEPO:US $ 321.98M 17.16M
Endo International Ordinary Shares ENDP:US $ 6362.26M 2084.95M
Halozyme Therapeutics HALO:US $ 1781.39M 619.14M
Horizon Pharma HZNP:US $ 8853.47M 113.14M
JAZZ PHA JAZZ:US $ 11200.13M 568.78M
Neurocrine Biosciences NBIX:US $ 2005.7M 138.8M
Pacira Pharmaceuticals PCRX:US $ 1733.99M 157.49M
Pain Therapeutics PTIE:US $ 227.38M 16.81M
Redhill Biopharma RDHL:US $ 167.05M 14.14M
Revance Therapeutics RVNC:US $ 561.88M 77.66M
Supernus Pharmaceuticals SUPN:US $ 1694.97M 55.46M
Teva Pharmaceutical Industries TEVA:US $ 45932M 1127M
Vanda Pharmaceuticals VNDA:US $ 609.1M 5.54M